Is SMMT or SPRY more undervalued in 2026?

CirclFi compares Summit Therapeutics Inc. (SMMT) and ARS Pharmaceuticals, Inc. (SPRY) using 13 institutional-grade valuation models. SMMT has a Quality of Company score of 4.4/10 while SPRY scores 4.7/10.

Which is a better buy — SMMT or SPRY?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do SMMT and SPRY valuations compare?

SMMT at $17.41 and SPRY at $9.40 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

SMMT vs SPRY Valuation Comparison 2026 — Intrinsic Value Analysis

SMMT

Biotechnology

Summit Therapeutics Inc.

Quality

4.4

out of 10

Value Trap

SAFE

Price

$17.41

Last close

Models

12/13

Active

SPRY

Biotechnology

ARS Pharmaceuticals, Inc.

Quality

4.7

out of 10

Value Trap

SAFE

Price

$9.40

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	SMMT Fair Value	SMMT Upside	SPRY Fair Value	SPRY Upside
Bayesian DCF	Intrinsic	$5.97	-65.7%	$2.27	-75.8%
Earnings Power Value	Intrinsic	$10.70	-51.5%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$2.38	-85.2%	$1.53	-83.7%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for SMMT vs SPRY — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SMMT vs SPRY — Which Stock Is More Undervalued?

SPRY scores higher with a 4.7/10 quality rating vs SMMT's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Summit Therapeutics Inc. (SMMT) and ARS Pharmaceuticals, Inc. (SPRY) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SMMT currently trades at $17.41 with a QOC of 4.4/10, while SPRY trades at $9.40 with a QOC of 4.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).